Videos

A key opinion leader in the treatment of FL provides insight on the decision of whether to add maintenance therapy to the treatment regimen.

Loretta Nastoupil, MD, discusses first-line therapy options for patients with newly diagnosed follicular lymphoma (ND FL).

Loretta Nastoupil, MD, describes the role of molecular testing used in risk stratification of patient with FL

Loretta Nastoupil, MD, reviews the case of a 75-year-old woman with relapsed/refractory follicular lymphoma (R/R FL).

Expert hematologist/oncologists discuss the use of early PI3K inhibitors in the management of R/R follicular lymphoma (FL) and MZL (marginal zone lymphoma).

Ian W. Flinn, MD, PhD, leads the discussion on the various PI3K isoforms and their role in lymphoma.

Ruben Mesa, MD, and panel discuss considerations for optimizing therapy in high risk myelofibrosis.

Experts in myelofibrosis present safety and efficacy data from a clinical trial of fedratinib in patients with high risk myelofibrosis.

Dr Jamile Shammo presents clinical trial data on the efficacy and safety of ruxolitinib in patients with high risk myelofibrosis.

Experts in MPN review data on predictors of response to ruxolitinib in high risk myelofibrosis.

Jamile Shammo, MD, reviews prognostic models in myelofibrosis.

Dr Jamile Shammo reviews the case of a 72-year-old man with primary myelofibrosis.

Experts in the management of breast cancer review some trials leading to the future of personalized treatment for HER2+ breast cancer.

Andrew Seidman, MD, follows the patient after TCHP therapy and discusses the risk of recurrence with the experts.

Ingrid Mayer, MD, MSCI, and panel share the benefits of subcutaneous HP instead of IV HP therapy, particularly for the patients’ quality of life.

The panel of experts reviews the use dual HER2-targeted therapy in HER2+ breast cancer.

Experts in breast cancer management discuss the use of anthracycline and risk of the cardiac toxicities.

Haris Ali, MD, discusses research supporting the use of ruxolitinib for the treatment of myelofibrosis.

Brandon Mahal, MD, discusses challenges facing prostate cancer equity.

Melissa Hardesty, MD, discusses the modern disease management of patients with ovarian cancer in the community setting.

Yousef Zakharia, MD, discusses the results of a phase 2 trial investigating concurrent durvalumab and radiation therapy followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder.

Leonard G. Gomella, MD, discusses deciding between active surveillance and precision medicine in mutated prostate cancer.

Experts in polycythemia vera review data regarding the role of symptomatic improvement in overall outcome in patients with polycythemia vera.

Prithviraj Bose, MD, and colleagues discuss treatment options for high risk polycythemia vera.

The experts discuss the REACH3 trial in steroid-refractory chronic GVHD and what they hope to see in the future of treating chronic GVHD.

The experts present and discuss the case of a patient with steroid-refractory chronic GVHD and discuss treatment options.

Constantine S. Tam, MD, discusses how ibrutinib plus venetoclax regimen from the SYMPATICO 2938 trial may fit in the relapsed/refractory mantle cell lymphoma setting.

Thomas Marron, PhD, MD, discusses the safety and tolerability of neoadjuvant sunitinib in hepatocellular carcinoma.

Charles Powell, MD, MBA, discusses the questions surrounding pulmonary toxicities when using anti-HER2 monoclonal antibodies such as trastuzumab deruxtecan for patients with HER2-positive metastatic breast cancer.

Annelise Wilhite, MD, discusses a clinical investigation of survival in patients with vulvar/vaginal melanomas.